Rosa Isela Gallagher

Senior Research Scientist

George Mason University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (37)

Purpose: Pretreatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify prespecified biomarkers associated with response to the regimen of paclitaxel, the anti–type I insulin-like growth factor receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared with control therapy (paclitaxel followed by AC). The primary endpoint of this trial is pathologic complete response (pCR). Experimental Design: One hundred six patients treated with PGM and 119 contemporary controls were evaluated using laser capture microdissection and reverse-phase protein array to evaluate 32 prespecified potential predictive biomarkers in the IGF-1R pathway and 109 additional exploratory endpoints. Results: Total levels of IGF-1R were poorly correlated with phosphorylated IGF-1R/insulin receptor (IR). Higher levels of phosphorylated IGF-1R/IR were associated with an increased likelihood of obtaining pCR, especially in the hormone receptor (HR)–positive subgroup. Markers of immune response also showed an association with pCR but differed between HR+ and HR− subgroups. In HR− tumors, phospho-STAT1 Y701 and low levels of phospho-p27 associated with pCR. These relationships were not observed in patients treated with control chemotherapy. Conclusions: Activation status of IGF-1R/IR associated with increased pCR to PGM in HR+ breast cancers. Immune activation markers were also associated with response in HR+ and HR− subgroups. Thus, IGF-1R may directly regulate tumor biology and associate with immune response to therapy.

Year:

2025

Purpose: Immune checkpoint inhibitors (ICI) have increasing application in endometrial cancer, underscoring the need for robust biomarkers for patient selection. JAK1 pathogenic variants (PV) have previously been implicated in immune evasion. In this study, we identify biomarkers predictive of ICI response in endometrial cancer and the implications of JAK1 PVs in this context. Experimental Design: This is a translational study of tumors from 84 patients with endometrial cancer treated with ICIs. High-throughput proteomic-based profiling was used to quantify 193 phosphoprotein/protein expression levels, including key JAK/STAT signaling pathway components. Associations with clinical outcomes were assessed using multivariate regression analysis. The functional consequences of JAK1 PVs were explored through in vitro signaling assays and analyses of The Cancer Genome Atlas database. Results: MHC-I expression correlated with improved progression-free survival (P = 0.035), validated in orthogonal approaches. Notably, a subset of patients harboring JAK1 PVs demonstrated exceptional survival on ICIs. In The Cancer Genome Atlas cohort of microsatellite instability–high and DNA polymerase epsilon–mutated tumors, homozygous loss of JAK1 trended toward decreased survival, whereas heterozygous loss of JAK1 was associated with significantly improved survival (P = 0.026), suggesting partial retention of antigen presentation pathways. Among our ICI-treated microsatellite instability–high tumor samples, NK cell marker NCAM1 was associated with improved survival (P = 0.02). Conclusions: These data support MHC-I as a potential predictive biomarker for ICI response in endometrial cancer. Additionally, we show that partial retention of JAK1 signaling in JAK1 tumors with heterozygous loss is associated with improved survival, potentially attributable to enhanced NK cell activity in tumors with low MHC-I expression.

Year:

2025

Purpose: Immune checkpoint inhibitors (ICI) have increasing application in endometrial cancer, underscoring the need for robust biomarkers for patient selection. JAK1 pathogenic variants (PV) have previously been implicated in immune evasion. In this study, we identify biomarkers predictive of ICI response in endometrial cancer and the implications of JAK1 PVs in this context. Experimental Design: This is a translational study of tumors from 84 patients with endometrial cancer treated with ICIs. High-throughput proteomic-based profiling was used to quantify 193 phosphoprotein/protein expression levels, including key JAK/STAT signaling pathway components. Associations with clinical outcomes were assessed using multivariate regression analysis. The functional consequences of JAK1 PVs were explored through in vitro signaling assays and analyses of The Cancer Genome Atlas database. Results: MHC-I expression correlated with improved progression-free survival ( P = 0.035), validated in orthogonal approaches. Notably, a subset of patients harboring JAK1 PVs demonstrated exceptional survival on ICIs. In The Cancer Genome Atlas cohort of microsatellite instability–high and DNA polymerase epsilon–mutated tumors, homozygous loss of JAK1 trended toward decreased survival, whereas heterozygous loss of JAK1 was associated with significantly improved survival ( P = 0.026), suggesting partial retention of antigen presentation pathways. Among our ICI-treated microsatellite instability–high tumor samples, NK cell marker NCAM1 was associated with improved survival ( P = 0.02). Conclusions: These data support MHC-I as a potential predictive biomarker for ICI response in endometrial cancer. Additionally, we show that partial retention of JAK1 signaling in JAK1 tumors with heterozygous loss is associated with improved survival, potentially attributable to enhanced NK cell activity in tumors with low MHC-I expression.

Year:

2025

Purpose: Pretreatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify prespecified biomarkers associated with response to the regimen of paclitaxel, the anti–type I insulin-like growth factor receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared with control therapy (paclitaxel followed by AC). The primary endpoint of this trial is pathologic complete response (pCR). Experimental Design: One hundred six patients treated with PGM and 119 contemporary controls were evaluated using laser capture microdissection and reverse-phase protein array to evaluate 32 prespecified potential predictive biomarkers in the IGF-1R pathway and 109 additional exploratory endpoints. Results: Total levels of IGF-1R were poorly correlated with phosphorylated IGF-1R/insulin receptor (IR). Higher levels of phosphorylated IGF-1R/IR were associated with an increased likelihood of obtaining pCR, especially in the hormone receptor (HR)–positive subgroup. Markers of immune response also showed an association with pCR but differed between HR+ and HR− subgroups. In HR− tumors, phospho-STAT1 Y701 and low levels of phospho-p27 associated with pCR. These relationships were not observed in patients treated with control chemotherapy. Conclusions: Activation status of IGF-1R/IR associated with increased pCR to PGM in HR+ breast cancers. Immune activation markers were also associated with response in HR+ and HR− subgroups. Thus, IGF-1R may directly regulate tumor biology and associate with immune response to therapy.

Year:

2025

Purpose: Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR) rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage triple-negative, and possibly high-risk estrogen receptor–positive breast cancer. However, immunotherapy has been associated with significant toxicity, and most patients treated with NAC do not require immunotherapy to achieve pCR. Biomarkers discerning patients benefitting from the addition of immunotherapy from those who would achieve pCR to NAC alone are clearly needed. In this study, we tested the ability of MHC-II expression on tumor cells, to predict immunotherapy-specific benefit in the neoadjuvant breast cancer setting. Patients and Methods: This was a retrospective tissue-based analysis of 3 cohorts of patients with breast cancer: (i) primary nonimmunotherapy-treated breast cancers ( n = 381), (ii) triple-negative breast cancers (TNBC) treated with durvalumab and standard NAC ( n = 48), and (iii) HER2-negative patients treated with standard NAC ( n = 87) or NAC and pembrolizumab ( n = 66). Results: HLA-DR positivity on ≥5% of tumor cells, defined a priori , was observed in 10% and 15% of primary non-immunotherapy–treated hormone receptor–positive and triple-negative breast cancers, respectively. Quantitative assessment of MHC-II on tumor cells was predictive of durvalumab + NAC and pembrolizumab + NAC (ROC AUC, 0.71; P = 0.01 and AUC, 0.73; P = 0.001, respectively), but not NAC alone (AUC, 0.5; P = 0.99). Conclusions: Tumor-specific MHC-II has a strong candidacy as a specific biomarker of anti–PD-1/L1 immunotherapy benefit when added to standard NAC in HER2-negative breast cancer. Combined with previous studies in melanoma, MHC-II has the potential to be a pan-cancer biomarker. Validation is warranted in existing and future phase II/III clinical trials in this setting.

Year:

2024

Supplementary Figure 1: CONSORT diagrams for associated studies. Supplementary Figure 2: Tumor specific MHC-II pattern immunofluorescence in ER+ and TNBC. Supplementary Figure 3: Non-tumor MHC-II expression and comparison of PD-L1+ and HLA-DR+ patient populations. Supplementary Figure 4: RPPA associations with pCR for control and pembrolizumab-treated (Treat) arms, by clinical group. Supplementary Figure 5: RPPA associations with pCR for control and pembrolizumab-treated arms in high-risk ER+ patients.

Year:

2024

Supplementary Methods: detailed protocol. Supplementary Table 1: Antibodies used for RPPA. Supplementary Table 2: Rates of tumor-specific MHC-II/HLA-DR expression across HER2-negative primary breast cancers. Supplementary Table 3: Univariate and multivariate analysis for achieving pCR to pembrolizumab and neoadjuvant chemotherapy or chemotherapy alone. Supplementary Table 4: Cox proportional Hazard ratio univariate analysis for 3-year event-free survival associated with pembrolizumab and neoadjuvant chemotherapy or chemotherapy alone. Supplementary Figure legends.

Year:

2024

Supplemental Figure 7. B7-H4 and PD-L1 are not mutually exclusive on tumor cells. Data shown are reverse phase protein array expression data of B7-H4 and PD-L1 (SP142, 22C3, or Atezolizumab) from the I-SPY2 patient cohort. Samples were a mixture of TNBC and ER+ tumors and were treated with chemotherapy ± anti-PD-1. Depending on the antibody clone selected to detect PD-L1 expression, B7-H4 had no correlation, or a positive correlation to PD-L1 expression in these tumors. Data analyzed by spearman correlation and shown with linear regression best-fit line. n = 151 patients.

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (36)

Nola Hylton

Professor

University of California, San Francisco

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Michelle Melisko

Clinical Professor of Medicine

University of California, San Francisco

UNITED STATES
View details

Vijaya Bharti

Research assistant professor

Vanderbilt University

UNITED STATES
View details

Amy Clark

Assistant Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Amy Jo Chien

Professor of Clinical Medicine Medical Director, Breast Oncology

University of California, San Francisco

UNITED STATES
View details

Sarah Blair

Professor

UC San Diego Health System

UNITED STATES
View details

Erica Carballo

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

W. Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

brian lehmann

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Payal D. Shah

University of Pennsylvania

UNITED STATES
View details

Kathy Albain

Professor of Medicine

Loyola University Chicago Stritch School of Medicine

UNITED STATES
View details

Julie E. Lang

University of Southern California

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Rita Nanda

Associate Professor of Medicine; Director Breast Oncology

University of Chicago

UNITED STATES
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Yunn-Yi Chen

Professor

UCSF Medical Center

UNITED STATES
View details

Erica M. Stringer-Reasor

Associate Professor

The University of Alabama

UNITED STATES
View details

Tarah Ballinger

Associate Professor of Medicine

Indiana University School of Medicine

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Cesar Santa-Maria

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Andres Ocampo

Vanderbilt University

UNITED STATES
View details

Juliana Bronzini

Vanderbilt University

UNITED STATES
View details

Douglas Yee

Professor

University of Minnesota

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

John T. Wilson

Vanderbilt University

UNITED STATES
View details

Vandana Abramson

Professor of Medicine

-

UNITED STATES
View details

BJ Rimel

Division Chief, Gynecologic Oncology

Fred Hutch Cancer Center

UNITED STATES
View details

Courtney Penn

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Quanhu Sheng

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

David Potter

Associate Professor

University of Minnesota

UNITED STATES
View details